Lastly, AMG 397 is an oral small-molecule inhibitor of Mcl-1 and is the only orally available Mcl-1 inhibitor in a phase I trial for MM, AML, NHL, or DLBCL (NCT03465540), though the FDA placed this trial on hold due to concerns for cardiac toxicity and the pharmaceutical company, Amgen, also suspended clinical trials with AMG 176 as a precaution. The gene discussed is MCL1; the disease is diffuse large B-cell lymphoma.